Tag: Ozempic

Why Generic Semaglutide Is Becoming Cheaper in Canada While the US Still Waits Canadian patients gain early access to lower cost weight loss medication Canada has approved generic versions of semaglutide, a GLP 1 drug used for type 2 diabetes and weight loss. This move is expected to cut costs significantly and improve access for patients who rely on these treatments. One Canadian patient, Elizabeth Doran from Ottawa, has been using GLP 1 medication for nearly a year. She was prescribed Wegovy because she had not yet developed diabetes. Her condition included prediabetes and high blood pressure, which placed her just below the threshold for full diabetes treatment coverage. Since she did not qualify for insurance support under Ontario’s diabetes drug program, she had to pay between 350 and 500 Canadian dollars per month. To manage the cost, she worked extra teaching shifts and used manufacturer discount offers. New generic approval changes the pricing landscape Canada has now approved two generic semaglutide products. One is produced by India based Dr Reddy’s, and the other by Canadian company Apotex. These versions are expected to sell at less than one third of the price of branded options. This development could help millions of Canadians who already use GLP 1 medications, as well as many others who avoided treatment due to high costs. It has also pushed the original manufacturer to reduce prices in some markets. Why the US does not yet have cheaper alternatives In the United States, semaglutide drugs like Ozempic remain expensive, often costing over 1000 US dollars per month for people without insurance. Generics are not expected to enter the US market until around 2032. Patent protections and regulatory extensions allow pharmaceutical companies to maintain market exclusivity for many years. Experts say these rules delay cheaper competition even after demand for alternatives rises. Apotex has received tentative approval from the US Food and Drug Administration, but it cannot yet sell its generic version. Legal protections around semaglutide patents are still in place. Global pressure is already reshaping drug prices Other countries are also influencing pricing. India recently approved several low cost versions of semaglutide, which has already led to price cuts by the original manufacturer in that market. Experts say Canada’s early approval of generics may increase pressure on other regions to reconsider pricing and access policies, especially as demand for weight loss and diabetes treatments continues to grow worldwide.
Health

Why Generic Semaglutide Is Becoming Cheaper in Canada While the US Still Waits

Canadian patients gain early access to lower cost weight loss medication Canada…

Register Lost your password?